Abeona Therapeutics (ABEO)
(Real Time Quote from BATS)
$6.61 USD
+0.07 (1.07%)
Updated Oct 8, 2024 02:36 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Abeona Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 4 | 1 | 3 | 10 | 0 |
Cost Of Goods | 2 | 0 | 0 | 0 | 0 |
Gross Profit | 2 | 1 | 3 | 10 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 49 | 52 | 93 | 91 | 77 |
Income After Depreciation & Amortization | -47 | -51 | -90 | -81 | -77 |
Non-Operating Income | -7 | 12 | 9 | 1 | 1 |
Interest Expense | 0 | 1 | 4 | 4 | 0 |
Pretax Income | -54 | -40 | -85 | -84 | -76 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -54 | -40 | -85 | -84 | -76 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -54 | -40 | -85 | -84 | -76 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -44 | -46 | -85 | -77 | -69 |
Depreciation & Amortization (Cash Flow) | 3 | 5 | 4 | 5 | 8 |
Income After Depreciation & Amortization | -47 | -51 | -90 | -81 | -77 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 21.38 | 7.86 | 3.94 | 3.71 | 2.01 |
Diluted EPS Before Non-Recurring Items | -2.05 | -4.81 | -15.50 | -13.75 | -37.75 |
Diluted Net EPS (GAAP) | -2.53 | -5.53 | -21.50 | -22.75 | -37.75 |
Fiscal Year end for Abeona Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.03 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | -0.03 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 17.87 | 14.33 | 13.18 | 11.34 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -17.87 | -14.33 | -13.21 | -11.34 |
Non-Operating Income | NA | 26.34 | -16.30 | -3.27 | -0.40 |
Interest Expense | NA | 1.07 | 0.95 | 0.11 | 0.11 |
Pretax Income | NA | 7.41 | -31.58 | -16.59 | -11.84 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 7.41 | -31.58 | -16.59 | -11.84 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 7.41 | -31.58 | -16.59 | -11.84 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 51.23 | 27.32 | 25.92 | 24.80 |
Diluted EPS Before Non-Recurring Items | NA | -0.75 | -0.53 | -0.64 | -0.48 |
Diluted Net EPS (GAAP) | NA | -0.26 | -1.16 | -0.59 | -0.48 |